<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698189</url>
  </required_header>
  <id_info>
    <org_study_id>8628-005</org_study_id>
    <secondary_id>2015-005487-42</secondary_id>
    <secondary_id>MK-8628-005</secondary_id>
    <nct_id>NCT02698189</nct_id>
  </id_info>
  <brief_title>A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)</brief_title>
  <official_title>A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the recommended dose of MK-8628 for further studies in
      participants with acute myeloid leukemia (AML) including AML de novo and AML secondary to
      myelodysplastic syndrome (MDS) and in participants with diffuse large B cell lymphoma
      (DLBCL). The recommended dose will be established by evaluating dose limiting toxicity (DLT),
      safety, tolerability, and early efficacy signals.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 19, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Dose Limiting Toxicity (DLT)</measure>
    <time_frame>From time of first dose up to the end of Cycle 1 (21-day cycle): up to 21 days</time_frame>
    <description>DLT was any of the following drug related (DR) investigator-assessed adverse events: pancytopenia with hypocellular bone marrow and no marrow blasts lasting for ≥6 weeks; Grade (G)4 hematologic toxicity lasting ≥7 days except thrombocytopenia; G4 thrombocytopenia; G3 thrombocytopenia with bleeding; G3 or 4 febrile or infection-related neutropenia; G4 nonhematologic (NH) toxicity (not laboratory); G3 NH toxicity (not laboratory), nausea, vomiting, or diarrhea lasting &gt;3 days despite supportive care; G3 or 4 NH laboratory abnormality requiring medical intervention, hospitalization, or persisting &gt;1 week; increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, or international normalization ratio indicative of significant liver impairment; DR adverse event leading to discontinuation or ≥20% missed planned doses in Cycle 1; DR toxicity causing &gt;2 week delay in starting Cycle 2; or G5 toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced At Least One Adverse Event (AE)</measure>
    <time_frame>From time of first dose until the end of follow-up (up to 8 months)</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of all participants who experienced at least one AE is presented. These safety results are based on a 09-May-2018 data cutoff date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>From time of first dose until the end of treatment (up to 7 months)</time_frame>
    <description>The percentage of all participants who discontinued study treatment due to an AE is presented. These results are based on a 09-May-2018 data cutoff date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</measure>
    <time_frame>Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months)</time_frame>
    <description>ORR was defined as the percentage of the participants who had complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR. The percentage of participants who achieved CR or PR is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</measure>
    <time_frame>Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months)</time_frame>
    <description>ORR was defined as the percentage of the participants who had complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal). The percentage of participants who achieved CR or PR is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</measure>
    <time_frame>Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months)</time_frame>
    <description>DOR was defined as the time from complete response (CR) or partial response (PR) to documented disease progression or death as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</measure>
    <time_frame>Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months)</time_frame>
    <description>DOR was defined as the time from complete response (CR) or partial response (PR) to documented disease progression or death as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</measure>
    <time_frame>Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months)</time_frame>
    <description>DCR was defined as the percentage of the participants who had stable disease, complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</measure>
    <time_frame>Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months)</time_frame>
    <description>DCR was defined as the percentage of the participants in the DLBCL cohort who had stable disease, complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Concentration (Cmax) of MK-8628</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine Cmax at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Cmax for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Cmax of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of MK-8628</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine Tmax at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Tmax for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Tmax of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Minimum Concentration (Cmin) of MK-8628</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine Cmin at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Cmin for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Cmin of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞)</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine AUC 0-∞ at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, AUC 0-∞ for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The AUC 0-∞ of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) for MK-8628</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine t1/2 at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, t1/2 for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The t1/2 of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) of MK-8628</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine CL/F at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, CL/F for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The CL/F of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628</measure>
    <time_frame>Up to 22 days post MK-8628 dose</time_frame>
    <description>Blood samples were collected to determine Vz/F at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Vz/F for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Vz/F of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 3 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</measure>
    <time_frame>Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 3 hours postdose on Day 1 of Cycle 1 (21-day cycle)</time_frame>
    <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 3 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 3 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 8 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</measure>
    <time_frame>Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 8 hours postdose on Day 1 of Cycle 1 (21-day cycle)</time_frame>
    <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 8 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 8 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 12 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</measure>
    <time_frame>Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 12 hours postdose on Day 1 of Cycle 1 (21-day cycle)</time_frame>
    <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 12 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 12 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at Predose on Day 8 of Cycle 1 (21-day Cycle)</measure>
    <time_frame>Baseline (predose on Day 1 of Cycle 1) and predose on Day 8 of Cycle 1 (21-day cycle)</time_frame>
    <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose on Day 1 and predose on Day 8 of Cycle 1 (21-day cycle) using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at predose Day 8/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>AML Including AML de Novo and AML Secondary to MDS</condition>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>MK-8628 20 mg AML Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-8628 20 mg DLBCL Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8628 Dose 20 mg</intervention_name>
    <description>Administered as an oral capsule twice a day for 21 consecutive days per cycle.</description>
    <arm_group_label>MK-8628 20 mg AML Cohort</arm_group_label>
    <arm_group_label>MK-8628 20 mg DLBCL Cohort</arm_group_label>
    <other_name>OTX015</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AML (AML de novo and post-MDS) or DLBCL

          -  AML participants must have the following malignancy criteria: measurable and evaluable
             disease per tumor response criteria; ≥ 5% bone marrow blasts without alternate
             causality; and &gt; 90 days since allogeneic stem cell transplantation relapse in
             participants relapsing after transplant

          -  AML participants who are Philadelphia chromosome positive must have received ≥ 2 lines
             of therapy, including 2 bcr-abl tyrosine-kinase (TK) inhibitors (among imatinib,
             nilotinib and dasatinib), or only 1 line including 1 TK inhibitor if the
             relapse/refractoriness is associated with the detection of a resistance mutation to
             these inhibitors

          -  AML participants &lt; 60 years old must be in second or further relapse or relapsing
             after allogeneic stem cell transplantation regardless of number of relapses

          -  AML participants ≥ 60 years old in first relapse with a disease-free interval &lt; 12
             months, or further relapse. First relapse is also applicable to AML post-MDS patients
             who have received prior treatment for MDS, but have not received prior treatment for
             AML.

          -  DLBCL participants must have the following malignancy criteria: measurable and
             evaluable disease per tumor response criteria and ≥ 1 tumor mass that is ≥ 15 mm (long
             axis of lymph node) or ≥ 10 mm (short axis of lymph node or extranodal lesions) on
             spiral CT scan; failed 2 standard lines of therapy (at least one containing an
             anti-CD20 monoclonal antibody), or for whom such treatment is contraindicated.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1

          -  An interval of ≥3 weeks since chemotherapy (≥ 6 weeks for nitrosoureas or mitomycin
             C), immunotherapy, hormone therapy or any other anticancer therapy or surgical
             intervention resection, or ≥3 half-lives for monoclonal antibodies, or ≥ 5 half-lives
             for other non-cytotoxic agents (whichever is longer)

          -  Female participants must not be pregnant (negative urine or serum human chorionic
             gonadotropin test within 72 hours of study start)

          -  Female and male participants of reproductive potential must agree to use adequate
             contraception starting from the first dose of trial treatment through 90 days after
             the last dose of study medication

        Exclusion Criteria:

          -  Known primary central nervous system (CNS) malignancy or symptomatic or untreated CNS
             metastases

          -  History of prior or concomitant malignancies within 3 years of study start

          -  Has other serious illness or medical condition, such as active infection, unresolved
             bowel obstruction, psychiatric disorders, or cerebrovascular accident within 1 year of
             study start

          -  Known history of human immunodeficiency virus (HIV) and/or active Hepatitis B or C
             infections

          -  Has one of the following cardiac-related conditions: Congestive heart failure; angina
             pectoris; myocardial infarction (within 1 year of study start); uncontrolled
             hypertension; or uncontrolled arrhythmias

          -  Is receiving other concomitant anticancer treatment

          -  Has received high dose chemotherapy followed by autologous stem cell transplantation
             less than 90 days prior to first dose of study treatment

          -  Is receiving concomitant therapy with strong CYP3A4 or CYP2A6 inhibitors or inducers

          -  Is pregnant or breast-feeding

          -  Participation in a clinical trial involving an investigational drug within 30 days of
             study start

          -  Known additional malignancy that is progressing or requires active treatment

          -  Has been previously treated with a Bromodomain and Extra-terminal (BET) inhibitor

          -  Has acute promyelocytic leukemia, clinically uncontrolled disseminated intravascular
             coagulation, or peripheral cytopenia

          -  Has chronic graft versus host disease (GVHD) or on immunosuppressive therapy for the
             control of GVHD

          -  Has uncontrolled disease-related metabolic disorder

          -  Unable to swallow oral medications, or has gastrointestinal condition deemed to
             jeopardize intestinal absorption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <results_first_submitted>December 19, 2018</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2019</results_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02698189/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrollment to the study was discontinued early based on a decision to terminate the MK-8628 program and based on limited efficacy signals and not due to safety-related concerns. This results disclosure is based on a data cutoff date of 09-May-2018; at which time 1 participant was ongoing in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK-8628 20 mg Acute Myeloid Leukemia (AML) Cohort</title>
          <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
        </group>
        <group group_id="P2">
          <title>MK-8628 20 mg Diffuse Large B Cell Lymphoma (DLBCL) Cohort</title>
          <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still ongoing in the study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>MK-8628 20 mg AML Cohort</title>
          <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
        </group>
        <group group_id="B2">
          <title>MK-8628 20 mg DLBCL Cohort</title>
          <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="17.3"/>
                    <measurement group_id="B2" value="63.8" spread="17.8"/>
                    <measurement group_id="B3" value="60.6" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log2 Transformed Normalized Gene Expression Ratios (GERs)</title>
          <description>GERs for 49 Bromodomain and Extra-Terminal (BET) target genes were measured using messenger Ribonucleic Acid (mRNA) predose on Day 1 of Cycle 1 (21-day cycle). The expression level of target genes was quantitated by quantitative polymerase chain reaction and the data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Baseline normalized GERs were expressed in logarithmic scale with a base of 2 (Log2 scale). Positive values=greater expression and negative values=reduced expression of any gene relative to housekeeping genes.</description>
          <units>Gene expression ratio (Log2 scale)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Agmatinase (AGMAT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.659" spread="0.888"/>
                    <measurement group_id="B2" value="-3.731" spread="0.573"/>
                    <measurement group_id="B3" value="-4.040" spread="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin A3 (ANXA3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.568" spread="1.944"/>
                    <measurement group_id="B2" value="0.602" spread="1.399"/>
                    <measurement group_id="B3" value="-0.455" spread="2.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atonal BHLH Transcription Factor 8 (ATOH8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-6.560" spread="0.756"/>
                    <measurement group_id="B2" value="-4.511" spread="0.851"/>
                    <measurement group_id="B3" value="-5.194" spread="1.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma Extra Large (BCL.xL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.744" spread="1.893"/>
                    <measurement group_id="B2" value="5.704" spread="1.588"/>
                    <measurement group_id="B3" value="4.718" spread="2.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma 2 (BCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.699" spread="1.369"/>
                    <measurement group_id="B2" value="0.479" spread="0.979"/>
                    <measurement group_id="B3" value="0.552" spread="1.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow X-linked Kinase (BMX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-6.109" spread="0.357"/>
                    <measurement group_id="B2" value="-2.408" spread="1.113"/>
                    <measurement group_id="B3" value="-3.642" spread="2.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase Recruitment Domain Family Member 6 (CARD6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.604" spread="0.490"/>
                    <measurement group_id="B2" value="-1.074" spread="0.364"/>
                    <measurement group_id="B3" value="-1.251" spread="0.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-C Motif Chemokine Receptor 1 (CCR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.566" spread="1.720"/>
                    <measurement group_id="B2" value="1.405" spread="0.863"/>
                    <measurement group_id="B3" value="0.415" spread="1.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cluster of Differentiation 163 (CD163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.586" spread="1.591"/>
                    <measurement group_id="B2" value="-1.789" spread="0.975"/>
                    <measurement group_id="B3" value="-2.722" spread="1.784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choline Kinase Alpha (CHKA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.255" spread="0.670"/>
                    <measurement group_id="B2" value="-0.795" spread="0.453"/>
                    <measurement group_id="B3" value="-0.112" spread="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemerin Chemokine-Like Receptor 1 (CMKLR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.967" spread="0.997"/>
                    <measurement group_id="B2" value="-0.952" spread="1.111"/>
                    <measurement group_id="B3" value="-1.290" spread="1.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine/Serine-Rich Nuclear Protein 2 (CSRNP2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.934" spread="0.399"/>
                    <measurement group_id="B2" value="-2.765" spread="0.228"/>
                    <measurement group_id="B3" value="-2.821" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dicarbonyl and L-xylulose Reductase (DCXR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.026" spread="0.230"/>
                    <measurement group_id="B2" value="-0.326" spread="0.121"/>
                    <measurement group_id="B3" value="-0.209" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deoxyribonuclease 1 Like 3 (DNASE1L3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-5.842" spread="1.960"/>
                    <measurement group_id="B2" value="-4.857" spread="1.411"/>
                    <measurement group_id="B3" value="-5.186" spread="1.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fc Gamma Receptor Ia (FCGR1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.119" spread="2.707"/>
                    <measurement group_id="B2" value="1.992" spread="1.363"/>
                    <measurement group_id="B3" value="0.622" spread="2.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibroblast Growth Factor Receptor 1 (FGFR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.202" spread="2.427"/>
                    <measurement group_id="B2" value="-3.761" spread="0.669"/>
                    <measurement group_id="B3" value="-3.574" spread="1.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G Protein-Coupled Receptor 141 (GPR141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.185" spread="0.603"/>
                    <measurement group_id="B2" value="-2.022" spread="0.511"/>
                    <measurement group_id="B3" value="-2.076" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme A (GZMA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.640" spread="2.151"/>
                    <measurement group_id="B2" value="2.416" spread="1.002"/>
                    <measurement group_id="B3" value="1.397" spread="2.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme B (GZMB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.175" spread="3.390"/>
                    <measurement group_id="B2" value="2.558" spread="1.025"/>
                    <measurement group_id="B3" value="1.647" spread="2.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme K (GZMK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.730" spread="2.427"/>
                    <measurement group_id="B2" value="0.576" spread="1.356"/>
                    <measurement group_id="B3" value="-0.193" spread="1.988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H2A Histone Family Member X (H2AFX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.504" spread="0.215"/>
                    <measurement group_id="B2" value="-1.629" spread="0.379"/>
                    <measurement group_id="B3" value="-1.254" spread="0.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis A Virus Cellular Receptor 2 (HAVCR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.177" spread="0.391"/>
                    <measurement group_id="B2" value="-0.210" spread="0.670"/>
                    <measurement group_id="B3" value="-0.532" spread="0.744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B Basic Helix-Loop-Helix Protein 41 (HES6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.202" spread="1.520"/>
                    <measurement group_id="B2" value="-3.679" spread="1.156"/>
                    <measurement group_id="B3" value="-3.853" spread="1.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hexamethylene Bisacetamide Inducible 1 (HEXIM1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.037" spread="0.788"/>
                    <measurement group_id="B2" value="0.803" spread="0.229"/>
                    <measurement group_id="B3" value="0.548" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatocyte Growth Factor (HGF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.880" spread="3.142"/>
                    <measurement group_id="B2" value="-0.798" spread="0.668"/>
                    <measurement group_id="B3" value="0.095" spread="2.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histone Cluster 2 H2B Family Member F (HIST2H2BF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.317" spread="2.412"/>
                    <measurement group_id="B2" value="3.848" spread="0.440"/>
                    <measurement group_id="B3" value="3.337" spread="1.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibitor of Nuclear Factor-kB (IKBKE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.358" spread="0.494"/>
                    <measurement group_id="B2" value="-0.019" spread="0.186"/>
                    <measurement group_id="B3" value="-0.132" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 12 Receptor Subunit Beta 2 (IL12RB2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.576" spread="2.016"/>
                    <measurement group_id="B2" value="-2.592" spread="1.437"/>
                    <measurement group_id="B3" value="-2.920" spread="1.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 7 Receptor (IL7R)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.531" spread="2.292"/>
                    <measurement group_id="B2" value="2.816" spread="0.829"/>
                    <measurement group_id="B3" value="1.700" spread="2.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunatic Fringe (Drosophila) Homolog (LFNG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.931" spread="0.722"/>
                    <measurement group_id="B2" value="0.671" spread="0.549"/>
                    <measurement group_id="B3" value="0.137" spread="0.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Immunoglobulin Like Receptor A4 (LILRA4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-6.838" spread="1.271"/>
                    <measurement group_id="B2" value="-3.803" spread="1.630"/>
                    <measurement group_id="B3" value="-4.815" spread="2.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophage Receptor (MARCO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-5.927" spread="0.816"/>
                    <measurement group_id="B2" value="-1.022" spread="1.370"/>
                    <measurement group_id="B3" value="-2.657" spread="2.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane Spanning 4-Domains A2 (MS4A2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.308" spread="2.486"/>
                    <measurement group_id="B2" value="-4.689" spread="1.515"/>
                    <measurement group_id="B3" value="-4.229" spread="1.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class E Basic Helix-Loop-Helix Protein 39 (MYC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.727" spread="0.155"/>
                    <measurement group_id="B2" value="-0.004" spread="0.739"/>
                    <measurement group_id="B3" value="0.573" spread="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nudix Hydrolase 12 (NUDT12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.948" spread="2.918"/>
                    <measurement group_id="B2" value="-4.204" spread="0.700"/>
                    <measurement group_id="B3" value="-4.118" spread="1.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferating Cell Nuclear Antigen (PCNA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.861" spread="0.241"/>
                    <measurement group_id="B2" value="-2.212" spread="0.484"/>
                    <measurement group_id="B3" value="-1.762" spread="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein Tyrosine Phosphatase PTP-U2 (PTPRO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.546" spread="1.000"/>
                    <measurement group_id="B2" value="-2.704" spread="0.426"/>
                    <measurement group_id="B3" value="-3.318" spread="1.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17orf87 (SCIMP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.588" spread="2.237"/>
                    <measurement group_id="B2" value="1.073" spread="0.589"/>
                    <measurement group_id="B3" value="-0.481" spread="2.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serpin Family G Member 1 (SERPING1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.208" spread="1.584"/>
                    <measurement group_id="B2" value="0.864" spread="1.168"/>
                    <measurement group_id="B3" value="0.645" spread="1.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD353 Antigen (SLAMF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-3.950" spread="1.981"/>
                    <measurement group_id="B2" value="-2.729" spread="0.847"/>
                    <measurement group_id="B3" value="-3.136" spread="1.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stathmin 1 (STMN1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.382" spread="0.359"/>
                    <measurement group_id="B2" value="-0.358" spread="0.828"/>
                    <measurement group_id="B3" value="0.556" spread="1.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroglobulin (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.955" spread="1.255"/>
                    <measurement group_id="B2" value="-4.221" spread="0.440"/>
                    <measurement group_id="B3" value="-4.465" spread="0.806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIFA Inhibitor (TIFAB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.808" spread="1.959"/>
                    <measurement group_id="B2" value="-2.905" spread="0.754"/>
                    <measurement group_id="B3" value="-2.873" spread="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transmembrane Protein 150B (TMEM150B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-5.664" spread="0.887"/>
                    <measurement group_id="B2" value="-2.105" spread="0.391"/>
                    <measurement group_id="B3" value="-3.291" spread="1.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte Activation Antigen CD30 (TNFRSF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-4.865" spread="0.886"/>
                    <measurement group_id="B2" value="-0.925" spread="0.938"/>
                    <measurement group_id="B3" value="-2.238" spread="2.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Cell-Activating Factor (TNFSF13B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.117" spread="1.746"/>
                    <measurement group_id="B2" value="1.595" spread="0.587"/>
                    <measurement group_id="B3" value="1.103" spread="1.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuftelin 1 (TUFT1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-6.288" spread="1.491"/>
                    <measurement group_id="B2" value="-4.377" spread="0.519"/>
                    <measurement group_id="B3" value="-5.014" spread="1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nemitin (WDR47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.748" spread="0.319"/>
                    <measurement group_id="B2" value="-1.377" spread="0.139"/>
                    <measurement group_id="B3" value="-1.501" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-C Motif Chemokine Ligand 2 (XCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.728" spread="0.852"/>
                    <measurement group_id="B2" value="-0.820" spread="1.313"/>
                    <measurement group_id="B3" value="-1.456" spread="1.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Dose Limiting Toxicity (DLT)</title>
        <description>DLT was any of the following drug related (DR) investigator-assessed adverse events: pancytopenia with hypocellular bone marrow and no marrow blasts lasting for ≥6 weeks; Grade (G)4 hematologic toxicity lasting ≥7 days except thrombocytopenia; G4 thrombocytopenia; G3 thrombocytopenia with bleeding; G3 or 4 febrile or infection-related neutropenia; G4 nonhematologic (NH) toxicity (not laboratory); G3 NH toxicity (not laboratory), nausea, vomiting, or diarrhea lasting &gt;3 days despite supportive care; G3 or 4 NH laboratory abnormality requiring medical intervention, hospitalization, or persisting &gt;1 week; increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, or international normalization ratio indicative of significant liver impairment; DR adverse event leading to discontinuation or ≥20% missed planned doses in Cycle 1; DR toxicity causing &gt;2 week delay in starting Cycle 2; or G5 toxicity.</description>
        <time_frame>From time of first dose up to the end of Cycle 1 (21-day cycle): up to 21 days</time_frame>
        <population>The population consisted of all participants that received at least 85% of the planned dose of study drug (18 days) or experienced a DLT during Cycle 1 (21-day cycle).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML Cohort</title>
            <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
          <group group_id="O2">
            <title>MK-8628 20 mg DLBCL Cohort</title>
            <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Dose Limiting Toxicity (DLT)</title>
          <description>DLT was any of the following drug related (DR) investigator-assessed adverse events: pancytopenia with hypocellular bone marrow and no marrow blasts lasting for ≥6 weeks; Grade (G)4 hematologic toxicity lasting ≥7 days except thrombocytopenia; G4 thrombocytopenia; G3 thrombocytopenia with bleeding; G3 or 4 febrile or infection-related neutropenia; G4 nonhematologic (NH) toxicity (not laboratory); G3 NH toxicity (not laboratory), nausea, vomiting, or diarrhea lasting &gt;3 days despite supportive care; G3 or 4 NH laboratory abnormality requiring medical intervention, hospitalization, or persisting &gt;1 week; increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, or international normalization ratio indicative of significant liver impairment; DR adverse event leading to discontinuation or ≥20% missed planned doses in Cycle 1; DR toxicity causing &gt;2 week delay in starting Cycle 2; or G5 toxicity.</description>
          <population>The population consisted of all participants that received at least 85% of the planned dose of study drug (18 days) or experienced a DLT during Cycle 1 (21-day cycle).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.000" upper_limit="0.415"/>
                    <measurement group_id="O2" value="1" lower_limit="0.040" upper_limit="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>80% Bayesian credible interval based on a prior distribution of Beta (1, 1).</non_inferiority_desc>
            <other_analysis_desc>80% 2-sided Bayesian credible interval: lower = 0.000; upper = 0.415</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>80% Bayesian credible interval based on a prior distribution of Beta (1, 1).</non_inferiority_desc>
            <other_analysis_desc>80% 2-sided Bayesian credible interval: lower = 0.040; upper = 0.391</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced At Least One Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of all participants who experienced at least one AE is presented. These safety results are based on a 09-May-2018 data cutoff date.</description>
        <time_frame>From time of first dose until the end of follow-up (up to 8 months)</time_frame>
        <population>The analysis population consisted of all participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML Cohort</title>
            <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
          <group group_id="O2">
            <title>MK-8628 20 mg DLBCL Cohort</title>
            <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced At Least One Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of all participants who experienced at least one AE is presented. These safety results are based on a 09-May-2018 data cutoff date.</description>
          <population>The analysis population consisted of all participants who received at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE</title>
        <description>The percentage of all participants who discontinued study treatment due to an AE is presented. These results are based on a 09-May-2018 data cutoff date.</description>
        <time_frame>From time of first dose until the end of treatment (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML Cohort</title>
            <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
          <group group_id="O2">
            <title>MK-8628 20 mg DLBCL Cohort</title>
            <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE</title>
          <description>The percentage of all participants who discontinued study treatment due to an AE is presented. These results are based on a 09-May-2018 data cutoff date.</description>
          <population>The analysis population consisted of all participants who received at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</title>
        <description>ORR was defined as the percentage of the participants who had complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR. The percentage of participants who achieved CR or PR is presented.</description>
        <time_frame>Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants in the AML cohort who received at least one dose of study treatment and had data evaluable for ORR analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML Cohort</title>
            <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</title>
          <description>ORR was defined as the percentage of the participants who had complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR. The percentage of participants who achieved CR or PR is presented.</description>
          <population>The analysis population consisted of all participants in the AML cohort who received at least one dose of study treatment and had data evaluable for ORR analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</title>
        <description>ORR was defined as the percentage of the participants who had complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal). The percentage of participants who achieved CR or PR is presented.</description>
        <time_frame>Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants in the DLBCL cohort who received at least one dose of study treatment and had data evaluable for ORR analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg DLBCL Cohort</title>
            <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</title>
          <description>ORR was defined as the percentage of the participants who had complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal). The percentage of participants who achieved CR or PR is presented.</description>
          <population>The analysis population consisted of all participants in the DLBCL cohort who received at least one dose of study treatment and had data evaluable for ORR analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</title>
        <description>DOR was defined as the time from complete response (CR) or partial response (PR) to documented disease progression or death as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR.</description>
        <time_frame>Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants in the AML cohort who received at least one dose of study treatment and had data evaluable for DOR analysis. DOR could not be calculated because no participants met criteria for analysis: CR or PR and documented disease progression or death.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML Cohort</title>
            <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</title>
          <description>DOR was defined as the time from complete response (CR) or partial response (PR) to documented disease progression or death as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR.</description>
          <population>The analysis population consisted of all participants in the AML cohort who received at least one dose of study treatment and had data evaluable for DOR analysis. DOR could not be calculated because no participants met criteria for analysis: CR or PR and documented disease progression or death.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</title>
        <description>DOR was defined as the time from complete response (CR) or partial response (PR) to documented disease progression or death as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal).</description>
        <time_frame>Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants in the DLBCL cohort who received at least one dose of study treatment and had data evaluable for DOR analysis. DOR could not be calculated because no participants met criteria for analysis: CR or PR and documented disease progression or death.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg DLBCL Cohort</title>
            <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</title>
          <description>DOR was defined as the time from complete response (CR) or partial response (PR) to documented disease progression or death as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal).</description>
          <population>The analysis population consisted of all participants in the DLBCL cohort who received at least one dose of study treatment and had data evaluable for DOR analysis. DOR could not be calculated because no participants met criteria for analysis: CR or PR and documented disease progression or death.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</title>
        <description>DCR was defined as the percentage of the participants who had stable disease, complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR.</description>
        <time_frame>Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants in the AML cohort who received at least one dose of study treatment and had data evaluable for DCR analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML Cohort</title>
            <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)</title>
          <description>DCR was defined as the percentage of the participants who had stable disease, complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the AML cohort were assessed using bone marrow aspiration and hematologic criteria and response was evaluated based on European LeukemiaNet (Döhner et al, Blood, 2010). The criteria for complete response included: bone marrow blasts &lt;5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &gt;1.0 × 10^9/Liter; platelet count &gt;100 × 10^9/Liter; and independence of red cell transfusions. The criteria for partial response included: decrease of bone marrow blast percentage to 5% to 25%; decrease of pretreatment bone marrow blast percentage by at least 50%; and all hematologic criteria associated with CR.</description>
          <population>The analysis population consisted of all participants in the AML cohort who received at least one dose of study treatment and had data evaluable for DCR analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</title>
        <description>DCR was defined as the percentage of the participants in the DLBCL cohort who had stable disease, complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal).</description>
        <time_frame>Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months)</time_frame>
        <population>The analysis population consisted of all participants in the DLBCL cohort who received at least one dose of study treatment and had data evaluable for DCR analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg DLBCL Cohort</title>
            <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)</title>
          <description>DCR was defined as the percentage of the participants in the DLBCL cohort who had stable disease, complete response (CR) or partial response (PR) as assessed by investigator review. Participants in the DLBCL cohort were assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response was evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). The criteria for CR included complete metabolic (no/minimal fluorodeoxyglucose [FDG] uptake) and radiologic response (target lesions regress to ≤5 cm in longest transverse diameter of a lesion) and no new lesions. The criteria for PR included: partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of the product of the perpendicular diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by &gt;50% in length beyond normal).</description>
          <population>The analysis population consisted of all participants in the DLBCL cohort who received at least one dose of study treatment and had data evaluable for DCR analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="0.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Maximum Concentration (Cmax) of MK-8628</title>
        <description>Blood samples were collected to determine Cmax at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Cmax for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Cmax of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for Cmax analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Maximum Concentration (Cmax) of MK-8628</title>
          <description>Blood samples were collected to determine Cmax at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Cmax for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Cmax of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for Cmax analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) of MK-8628</title>
        <description>Blood samples were collected to determine Tmax at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Tmax for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Tmax of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the Tmax analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of MK-8628</title>
          <description>Blood samples were collected to determine Tmax at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Tmax for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Tmax of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the Tmax analysis.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Minimum Concentration (Cmin) of MK-8628</title>
        <description>Blood samples were collected to determine Cmin at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Cmin for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Cmin of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the Cmin analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Minimum Concentration (Cmin) of MK-8628</title>
          <description>Blood samples were collected to determine Cmin at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Cmin for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Cmin of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the Cmin analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞)</title>
        <description>Blood samples were collected to determine AUC 0-∞ at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, AUC 0-∞ for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The AUC 0-∞ of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the AUC 0-∞ analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞)</title>
          <description>Blood samples were collected to determine AUC 0-∞ at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, AUC 0-∞ for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The AUC 0-∞ of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the AUC 0-∞ analysis.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3580" spread="1340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Half-life (t1/2) for MK-8628</title>
        <description>Blood samples were collected to determine t1/2 at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, t1/2 for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The t1/2 of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the t1/2 analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) for MK-8628</title>
          <description>Blood samples were collected to determine t1/2 at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, t1/2 for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The t1/2 of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for the t1/2 analysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance (CL/F) of MK-8628</title>
        <description>Blood samples were collected to determine CL/F at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, CL/F for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The CL/F of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for CL/F analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/F) of MK-8628</title>
          <description>Blood samples were collected to determine CL/F at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, CL/F for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The CL/F of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for CL/F analysis.</population>
          <units>Liters/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628</title>
        <description>Blood samples were collected to determine Vz/F at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Vz/F for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Vz/F of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
        <time_frame>Up to 22 days post MK-8628 dose</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for Vz/F analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628</title>
          <description>Blood samples were collected to determine Vz/F at the following time points: Cycle 1 (21-day cycle) Day 1 at predose and 20 minutes, 1 hour, 2.25 hours, 3.25 hours, 8 hours and 12 hours postdose; Cycle 1 (21-day cycle) at predose on Days 8 and 15; and Cycle 2 (21-day cycle) at predose on Day 1. Per protocol, Vz/F for MK-8628 was assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The Vz/F of MK-8628 after oral administration is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received at least one dose of MK-8628 20 mg and had data available for Vz/F analysis.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 3 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</title>
        <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 3 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 3 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
        <time_frame>Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 3 hours postdose on Day 1 of Cycle 1 (21-day cycle)</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received one dose of MK-8628 20 mg on Day 1 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 3 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</title>
          <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 3 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 3 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received one dose of MK-8628 20 mg on Day 1 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
          <units>Log2 scale fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agmatinase (AGMAT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.466" spread="0.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin A3 (ANXA3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.182" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atonal BHLH Transcription Factor 8 (ATOH8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.296" spread="0.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma Extra Large (BCL.xL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.219" spread="0.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma 2 (BCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.053" spread="0.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow X-linked Kinase (BMX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.093" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase Recruitment Domain Family Member 6 (CARD6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.245" spread="0.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-C Motif Chemokine Receptor 1 (CCR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.246" spread="0.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cluster of Differentiation 163 (CD163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.457" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choline Kinase Alpha (CHKA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemerin Chemokine-Like Receptor 1 (CMKLR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.194" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine/Serine-Rich Nuclear Protein 2 (CSRNP2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dicarbonyl and L-xylulose Reductase (DCXR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.300" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deoxyribonuclease 1 Like 3 (DNASE1L3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.305" spread="0.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fc Gamma Receptor Ia (FCGR1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.360" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibroblast Growth Factor Receptor 1 (FGFR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="0.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G Protein-Coupled Receptor 141 (GPR141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.054" spread="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme A (GZMA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.198" spread="0.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme B (GZMB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.163" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme K (GZMK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.127" spread="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H2A Histone Family Member X (H2AFX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis A Virus Cellular Receptor 2 (HAVCR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.272" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B Basic Helix-Loop-Helix Protein 41 (HES6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" spread="0.594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hexamethylene Bisacetamide Inducible 1 (HEXIM1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.315" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatocyte Growth Factor (HGF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.461" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histone Cluster 2 H2B Family Member F (HIST2H2BF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.325" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibitor of Nuclear Factor-kB (IKBKE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.124" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 12 Receptor Subunit Beta 2 (IL12RB2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 7 Receptor (IL7R)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunatic Fringe (Drosophila) Homolog (LFNG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.182" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Immunoglobulin Like Receptor A4 (LILRA4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.403" spread="0.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophage Receptor (MARCO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.321" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane Spanning 4-Domains A2 (MS4A2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.646" spread="0.850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class E Basic Helix-Loop-Helix Protein 39 (MYC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.359" spread="0.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nudix Hydrolase 12 (NUDT12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.309" spread="0.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferating Cell Nuclear Antigen (PCNA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein Tyrosine Phosphatase PTP-U2 (PTPRO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.391" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17orf87 (SCIMP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.159" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serpin Family G Member 1 (SERPING1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.137" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD353 Antigen (SLAMF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.485" spread="0.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stathmin 1 (STMN1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.054" spread="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroglobulin (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.485" spread="0.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIFA Inhibitor (TIFAB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.405" spread="0.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transmembrane Protein 150B (TMEM150B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.283" spread="0.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte Activation Antigen CD30 (TNFRSF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.522" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Cell-Activating Factor (TNFSF13B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.135" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuftelin 1 (TUFT1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.282" spread="0.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nemitin (WDR47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.144" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-C Motif Chemokine Ligand 2 (XCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.365" spread="0.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 8 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</title>
        <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 8 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 8 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
        <time_frame>Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 8 hours postdose on Day 1 of Cycle 1 (21-day cycle)</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received one dose of MK-8628 20 mg on Day 1 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 8 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</title>
          <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 8 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 8 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received one dose of MK-8628 20 mg on Day 1 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
          <units>Log2 scale fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agmatinase (AGMAT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.493" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin A3 (ANXA3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" spread="0.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atonal BHLH Transcription Factor 8 (ATOH8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma Extra Large (BCL.xL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.169" spread="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma 2 (BCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.133" spread="0.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow X-linked Kinase (BMX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="1.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase Recruitment Domain Family Member 6 (CARD6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-C Motif Chemokine Receptor 1 (CCR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.257" spread="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cluster of Differentiation 163 (CD163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.640" spread="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choline Kinase Alpha (CHKA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.116" spread="0.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemerin Chemokine-Like Receptor 1 (CMKLR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.218" spread="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine/Serine-Rich Nuclear Protein 2 (CSRNP2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dicarbonyl and L-xylulose Reductase (DCXR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.536" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deoxyribonuclease 1 Like 3 (DNASE1L3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.306" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fc Gamma Receptor Ia (FCGR1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.126" spread="0.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibroblast Growth Factor Receptor 1 (FGFR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.125" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G Protein-Coupled Receptor 141 (GPR141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme A (GZMA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="1.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme B (GZMB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.262" spread="0.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme K (GZMK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H2A Histone Family Member X (H2AFX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis A Virus Cellular Receptor 2 (HAVCR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.294" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B Basic Helix-Loop-Helix Protein 41 (HES6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.378" spread="0.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hexamethylene Bisacetamide Inducible 1 (HEXIM1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.345" spread="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatocyte Growth Factor (HGF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.325" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histone Cluster 2 H2B Family Member F (HIST2H2BF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.239" spread="0.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibitor of Nuclear Factor-kB (IKBKE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.153" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 12 Receptor Subunit Beta 2 (IL12RB2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 7 Receptor (IL7R)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunatic Fringe (Drosophila) Homolog (LFNG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Immunoglobulin Like Receptor A4 (LILRA4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.151" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophage Receptor (MARCO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.441" spread="0.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane Spanning 4-Domains A2 (MS4A2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.232" spread="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class E Basic Helix-Loop-Helix Protein 39 (MYC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.481" spread="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nudix Hydrolase 12 (NUDT12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.295" spread="0.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferating Cell Nuclear Antigen (PCNA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein Tyrosine Phosphatase PTP-U2 (PTPRO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17orf87 (SCIMP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.246" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serpin Family G Member 1 (SERPING1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.162" spread="0.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD353 Antigen (SLAMF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.307" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stathmin 1 (STMN1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.091" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroglobulin (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.347" spread="0.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIFA Inhibitor (TIFAB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.257" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transmembrane Protein 150B (TMEM150B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.136" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte Activation Antigen CD30 (TNFRSF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.830" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Cell-Activating Factor (TNFSF13B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.112" spread="0.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuftelin 1 (TUFT1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.341" spread="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nemitin (WDR47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-C Motif Chemokine Ligand 2 (XCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.190" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 12 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</title>
        <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 12 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 12 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
        <time_frame>Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 12 hours postdose on Day 1 of Cycle 1 (21-day cycle)</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received two doses of MK-8628 20 mg on Day 1 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 12 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)</title>
          <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose and 12 hours postdose using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at 12 hours postdose Day 1/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received two doses of MK-8628 20 mg on Day 1 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
          <units>Log2 scale fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agmatinase (AGMAT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.287" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin A3 (ANXA3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atonal BHLH Transcription Factor 8 (ATOH8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.363" spread="0.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma Extra Large (BCL.xL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.071" spread="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma 2 (BCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow X-linked Kinase (BMX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase Recruitment Domain Family Member 6 (CARD6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.052" spread="0.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-C Motif Chemokine Receptor 1 (CCR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.108" spread="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cluster of Differentiation 163 (CD163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.528" spread="0.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choline Kinase Alpha (CHKA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.191" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemerin Chemokine-Like Receptor 1 (CMKLR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine/Serine-Rich Nuclear Protein 2 (CSRNP2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.128" spread="0.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dicarbonyl and L-xylulose Reductase (DCXR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.511" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deoxyribonuclease 1 Like 3 (DNASE1L3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.074" spread="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fc Gamma Receptor Ia (FCGR1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.126" spread="0.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibroblast Growth Factor Receptor 1 (FGFR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.193" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G Protein-Coupled Receptor 141 (GPR141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.040" spread="0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme A (GZMA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.110" spread="0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme B (GZMB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.225" spread="0.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme K (GZMK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H2A Histone Family Member X (H2AFX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis A Virus Cellular Receptor 2 (HAVCR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.181" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B Basic Helix-Loop-Helix Protein 41 (HES6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.257" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hexamethylene Bisacetamide Inducible 1 (HEXIM1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.308" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatocyte Growth Factor (HGF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.298" spread="0.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histone Cluster 2 H2B Family Member F (HIST2H2BF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.288" spread="0.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibitor of Nuclear Factor-kB (IKBKE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.092" spread="0.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 12 Receptor Subunit Beta 2 (IL12RB2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" spread="0.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 7 Receptor (IL7R)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunatic Fringe (Drosophila) Homolog (LFNG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Immunoglobulin Like Receptor A4 (LILRA4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophage Receptor (MARCO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.714" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane Spanning 4-Domains A2 (MS4A2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.332" spread="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class E Basic Helix-Loop-Helix Protein 39 (MYC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.376" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nudix Hydrolase 12 (NUDT12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.331" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferating Cell Nuclear Antigen (PCNA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.049" spread="0.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein Tyrosine Phosphatase PTP-U2 (PTPRO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.103" spread="0.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17orf87 (SCIMP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.143" spread="0.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serpin Family G Member 1 (SERPING1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.111" spread="0.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD353 Antigen (SLAMF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.394" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stathmin 1 (STMN1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroglobulin (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.792" spread="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIFA Inhibitor (TIFAB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.120" spread="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transmembrane Protein 150B (TMEM150B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.073" spread="0.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte Activation Antigen CD30 (TNFRSF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.447" spread="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Cell-Activating Factor (TNFSF13B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.119" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuftelin 1 (TUFT1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.279" spread="0.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nemitin (WDR47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.117" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-C Motif Chemokine Ligand 2 (XCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at Predose on Day 8 of Cycle 1 (21-day Cycle)</title>
        <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose on Day 1 and predose on Day 8 of Cycle 1 (21-day cycle) using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at predose Day 8/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
        <time_frame>Baseline (predose on Day 1 of Cycle 1) and predose on Day 8 of Cycle 1 (21-day cycle)</time_frame>
        <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received 14 doses of MK-8628 20 mg by Day 8 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8628 20 mg AML+DLBCL Cohorts</title>
            <description>Total number of participants from both cohorts (AML and DLBCL) received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at Predose on Day 8 of Cycle 1 (21-day Cycle)</title>
          <description>Fold change from baseline (predose on Day 1 of Cycle 1 [21-day cycle]) in normalized gene expression ratios (nGER) for 49 target genes was measured to assess target engagement of BET proteins predose on Day 1 and predose on Day 8 of Cycle 1 (21-day cycle) using quantitative polymerase chain reaction (qPCR). Data were normalized by the delta-delta cycle threshold (Ct) method using housekeeping genes. Fold change from baseline was calculated as nGER at predose Day 8/baseline in logarithmic scale with a base of 2 (Log2 scale). Per protocol, target genes were assessed across all study participants by dose and this assessment was not related to any specific disease cohort. The fold change in nGER for each target gene is presented for participants pooled from the AML and DLBCL cohorts since both cohorts received the same dose. A two-fold increase in gene expression indicated a +1 Log2 fold change. Conversely, a two-fold decrease in gene expression indicated a -1 Log2 fold change.</description>
          <population>The analysis population consisted of the total number of participants pooled from both cohorts (AML and DLBCL) who received 14 doses of MK-8628 20 mg by Day 8 of Cycle 1 (21-day cycle) and had data available for the gene expression analysis.</population>
          <units>Log2 scale fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Agmatinase (AGMAT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.759" spread="0.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Annexin A3 (ANXA3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.210" spread="0.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atonal BHLH Transcription Factor 8 (ATOH8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.869" spread="1.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma Extra Large (BCL.xL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.329" spread="1.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-cell Lymphoma 2 (BCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow X-linked Kinase (BMX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.115" spread="0.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caspase Recruitment Domain Family Member 6 (CARD6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.115" spread="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-C Motif Chemokine Receptor 1 (CCR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.490" spread="1.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cluster of Differentiation 163 (CD163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.442" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Choline Kinase Alpha (CHKA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.218" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemerin Chemokine-Like Receptor 1 (CMKLR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.708" spread="1.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cysteine/Serine-Rich Nuclear Protein 2 (CSRNP2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.119" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dicarbonyl and L-xylulose Reductase (DCXR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.696" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deoxyribonuclease 1 Like 3 (DNASE1L3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.386" spread="0.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fc Gamma Receptor Ia (FCGR1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.885" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibroblast Growth Factor Receptor 1 (FGFR1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.561" spread="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G Protein-Coupled Receptor 141 (GPR141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.333" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme A (GZMA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.572" spread="0.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme B (GZMB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.442" spread="1.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granzyme K (GZMK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.657" spread="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H2A Histone Family Member X (H2AFX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis A Virus Cellular Receptor 2 (HAVCR2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.722" spread="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class B Basic Helix-Loop-Helix Protein 41 (HES6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.364" spread="1.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hexamethylene Bisacetamide Inducible 1 (HEXIM1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.429" spread="0.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatocyte Growth Factor (HGF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.276" spread="0.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histone Cluster 2 H2B Family Member F (HIST2H2BF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.427" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhibitor of Nuclear Factor-kB (IKBKE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.166" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 12 Receptor Subunit Beta 2 (IL12RB2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.435" spread="1.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 7 Receptor (IL7R)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.301" spread="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lunatic Fringe (Drosophila) Homolog (LFNG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Immunoglobulin Like Receptor A4 (LILRA4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="1.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophage Receptor (MARCO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.197" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Membrane Spanning 4-Domains A2 (MS4A2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class E Basic Helix-Loop-Helix Protein 39 (MYC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.270" spread="0.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nudix Hydrolase 12 (NUDT12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="0.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proliferating Cell Nuclear Antigen (PCNA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein Tyrosine Phosphatase PTP-U2 (PTPRO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.007" spread="0.839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C17orf87 (SCIMP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.360" spread="1.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serpin Family G Member 1 (SERPING1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.170" spread="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD353 Antigen (SLAMF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.918" spread="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stathmin 1 (STMN1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.251" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroglobulin (TG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.399" spread="0.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIFA Inhibitor (TIFAB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.937" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transmembrane Protein 150B (TMEM150B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.222" spread="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte Activation Antigen CD30 (TNFRSF8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.464" spread="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Cell-Activating Factor (TNFSF13B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.094" spread="0.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuftelin 1 (TUFT1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.472" spread="0.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nemitin (WDR47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.263" spread="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-C Motif Chemokine Ligand 2 (XCL2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.666" spread="0.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety data was collected up to 30 days after last dose of study treatment (up to approximately 8 months).</time_frame>
      <desc>The safety population consisted of all participants that received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-8628 20 mg AML Cohort</title>
          <description>Participants in the AML cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
        </group>
        <group group_id="E2">
          <title>MK-8628 20 mg DLBCL Cohort</title>
          <description>Participants in the DLBCL cohort received 20 mg of MK-8628 as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Factor VII deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to limited pharmacokinetics sampling for t1/2, caution must be exercised when interpreting the results of t1/2, CL/F, and AUC 0-∞ results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

